Fig. 5

In-silico prediction and target validation using mimics and antimiRs (A) Analysis by GeneGo pathway reveals oncogenic targets for the respective miRNAs, (B) Immunocytochemistry performed in MDA-MB-231 breast cancer cell by mimics of miR-432, miR-662, miR-659, miR-921, miR-105, and miR-200c and observed their effects on targets p53,APC, p-β-catenin and BRCA1, (C) q-PCR analysis using mimic probes of miR-432, miR-21, miR-662, miR-659,miR-921,and miR-105 demonstrating an induction effect on targets APC, PTEN, BRCA1, CASP8, CASP3, ESRRA, MDM2, STAT3, PGR, p53, c-Myc, EphrinB2, ERBB2, and PAX5 (D) varied effects on respective targets using KD probes of miR-432, miR-21, miR-662, miR-659, miR-921 and miR-105, (E) Upper panel denotes immunoblots on targets p53, caspase 8, c-Myc, using mimics of miR-432, miR-105, miR-921, miR-662, miR-659, and miR-200c and lower panel denotes immunoblots on targets p53, Bcl2, and PTEN using KD probes of miR-21, miR-662, miR659, miR-921, miR-105 and miR 432 (F) In-situ hybridization in tissue microarrays of both tumor (upper panel) and its adjacent normal tissues (lower panels) using miR-21, U6 and Scr (scrambled) probes respectively